A Tale of Two Drugs

A close look at the rollouts of two recently-approved drugs, Kalydeco and Zaltrap, reveals startling differences in how companies value a drug and justify its price. It also provides a preview of a likely future in which extremely costly drugs are common.

Join us for a discuss of drug development in the modern pharmaceutical marketplace. Discussion will be lead by S&S’s Misha Angrist, PhD. Professor Angrist is interested in the unintended consequences of policies intended to promote innovation in healthcare, especially the Bayh-Dole Act and the Orphan Drug Act. He is also interested in the way orphan drugs are priced and the rationalizations for those prices.

Suggested reading:

• Barry Werth, “A Tale of Two Drugs,” MIT Technology Review, October 22, 2013. Available here.